Ironwood Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Business context and period. Unaudited results cover the three months ended March 31, 2023, compared with Q1 2022. Ironwood is a gastrointestinal therapeutics company; most revenue comes from its U.S. LINZESS collaboration with AbbVie, which shares U.S. net profits and development costs equally with Ironwood. The filing was signed May 4, 2023. Dollar amounts below are in U.S. dollars.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $104.1 million | $97.5 million |
| Operating expenses | $44.0 million | $39.7 million |
| Operating income | $60.1 million | $57.8 million |
| Net income | $45.7 million | $38.8 million |
| Basic / diluted EPS | $0.30 / $0.25 | $0.25 / $0.21 |
| Cash from operations | $80.2 million | $64.1 million |
- Revenue rose 6.7%, primarily because Ironwood’s share of U.S. LINZESS net profits increased $7.3 million, driven by higher prescription demand, partly offset by lower net price and channel inventory fluctuations.
- Operating margin was approximately 57.8%, versus 59.3% in Q1 2022; net margin was approximately 43.9%, versus 39.8%. Net income benefited from higher interest and investment income.
- R&D expense increased 18.7% to $12.8 million; SG&A increased 7.8% to $31.1 million. Total operating expenses rose 10.8%.
- Interest and investment income was $7.3 million, compared with $0.2 million, mainly reflecting higher interest rates and investment balances. Interest expense fell to $1.5 million from $2.3 million, partly because the 2022 notes had been repaid at maturity in June 2022.
- Income tax expense was $20.1 million, compared with $17.7 million; the filing says most of the provision is expected to be non-cash while tax-loss carryforwards remain available.
- Cash and cash equivalents were $740.3 million at March 31, up from $656.2 million at December 31, 2022. Including restricted cash, the total was $742.1 million. Operating cash flow was $80.2 million; investing outflow was negligible, and financing provided $4.0 million, mainly from option exercises.
- Convertible notes had $400.0 million aggregate principal outstanding ($396.7 million net carrying value): $200 million due in 2024 and $200 million due in 2026. Current liabilities were $23.8 million; operating lease liabilities totaled $19.2 million. Stockholders’ equity was $706.9 million, and accumulated deficit was $650.7 million.
Material changes and business developments
- U.S. LINZESS-related collaborative revenue was $101.6 million, versus $94.3 million. Revenue from international linaclotide partners remained comparatively small.
- The company reported no share repurchases in Q1 2023; the prior-year quarter included $90.5 million of repurchases. The $150 million repurchase program was completed in May 2022.
- Ironwood’s U.S. FDA supplemental application for linaclotide for functional constipation in patients aged 6–17 received priority review, with a PDUFA date of June 14, 2023. Pediatric safety and effectiveness are not established until approved.
- Ironwood continued the Phase II proof-of-concept study of IW-3300 for visceral pain conditions, including IC/BPS. COUR was conducting the CNP-104 study for primary biliary cholangitis; early T-cell response data were expected in the second half of 2023.
Outlook, risks and unusual items
- Management said cash on hand was expected to fund projected operating needs for at least the next 12 months and anticipated cash and operating inflows would cover near- and long-term obligations. These are forward-looking estimates and actual results could differ.
- Management expects LINZESS U.S. collaboration revenue to remain a significant share of revenue and expects substantial development and commercialization spending for the foreseeable future. The filing gives no specific revenue or earnings guidance.
- In April 2023, after quarter-end, Ironwood initiated a reduction of approximately 10% of headquarters-based personnel. It expected to substantially complete the reduction in Q2 and estimated $3.0–$5.5 million in restructuring costs, primarily severance and benefits.
- Also after quarter-end, Ironwood agreed to pay COUR a non-refundable $6.0 million upfront amount for a $6.6 million credit against specified future payments; the expense was expected in Q2 2023. The company’s option to license CNP-104 would require a further $35 million payment if exercised. Potential commercial milestones and royalties are additional.
- Key risks include reliance on AbbVie and U.S. LINZESS performance; pricing, rebates and channel inventory; development, regulatory and safety uncertainty for pipeline programs; competition and intellectual-property matters; and the ability to meet convertible-note obligations. The notes have fixed interest rates and no financial covenants. The filing reported no material change in risk factors from the 2022 Form 10-K.
- The 2022 note hedge warrants expired unexercised in April 2023. The 2024 and 2026 convertible notes remain outstanding; capped calls may reduce dilution only within their contractual price range.
Important facts for investors to verify
- AbbVie’s reported LINZESS U.S. sales, net pricing, inventory levels and cost-sharing settlements, which drive most Ironwood revenue.
- FDA action on the pediatric functional-constipation application by the June 14, 2023 PDUFA date, and any resulting launch costs or revenue contribution.
- Progress and data timing for IW-3300 and CNP-104, including whether Ironwood exercises its CNP-104 license option and the related payments.
- Actual restructuring costs and savings following the workforce reduction, compared with the $3.0–$5.5 million estimate.
- Cash generation and investment returns, use of cash, and plans for the $200 million 2024 and $200 million 2026 convertible-note maturities.